Kirsten E. Peters

proteomics international

H指数:21

被引数:1,308

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Clinical Validation of a Diagnostic Test for Esophageal Adenocarcinoma Based on a Novel Serum Glycoprotein Biomarker Panel: PromarkerEso

基于新型血清糖蛋白生物标志物面板（PromarkerEso）的食管腺癌诊断测试的临床验证

Proteomes

IF3.6

2026-08-220

OAAI

Prognostic value of a plasma protein-based biomarker test for chronic kidney disease complicating diabetes in Aboriginal Australians

糖尿病合并慢性肾病在澳大利亚原住民中血浆蛋白基生物标志物检测的预后价值

Internal Medicine Journal

IF1.5

2025-12-010

PRE

Evaluating the potential clinical practice impact of the PromarkerD blood test in people with type 2 diabetes in Australia

评估PromarkerD血液检测在澳大利亚2型糖尿病患者中潜在的临床实践影响

Internal Medicine Journal

IF1.5

2025-12-010

PRE

A Clinical Validation of a Diagnostic Test for Esophageal Adenocarcinoma Based on a Novel Serum Glycoprotein Biomarker Panel: PromarkerEso

基于新型血清糖蛋白生物标志物面板（PromarkerEso）的食管腺癌诊断试验临床验证

Proteomes 2025, Vol. 13, Page 23

IF3.6

2025-08-220

PRE

PromarkerD Versus Standard of Care Biochemical Measures for Assessing Future Renal Function Decline in Type 2 Diabetes

DIAGNOSTICS

IF3.3

2025-03-090

OAAI

Identification of plasma protein biomarkers for endometriosis and the development of statistical models for disease diagnosis

HUMAN REPRODUCTION

IF6.1

2024-12-240

OAAI

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores

JOURNAL OF CLINICAL MEDICINE

IF2.9

2023-05-011

OAAI

The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II

ACTA DIABETOLOGICA

IF2.9

2022-09-0911

OAAI

Demonstrating the Economic Health Benefit of Using the PromarkerD In Vitro Diagnostic Test in the Prediction of Diabetic Kidney Disease

DIABETES

IF7.5

2021-06-010

PRE

The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease

PROTEOMES

IF3.6

2020-10-286

OAAI

Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study

JOURNAL OF CLINICAL MEDICINE

IF2.9

2020-10-240

OAAI

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

PromarkerD在Canagliflozin心血管评估研究 (CANVAS) 中预测2型糖尿病患者肾功能下降

JOURNAL OF CLINICAL MEDICINE

IF2.9

2020-10-0611

OAAI

Validation of the PromarkerD Test for Predicting Renal Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

DIABETES

IF7.5

2020-06-011

PRE

Prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults: The Fremantle Diabetes Study Phase II

CLINICAL ENDOCRINOLOGY

IF2.4

2020-02-0317

PREAI

Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis

RESPIROLOGY

IF6.3

2019-08-0814

OAAI

Updated prevalence of monogenic diabetes in Australia: Fremantle Diabetes Study Phase 2

MEDICAL JOURNAL OF AUSTRALIA

IF8.5

2019-07-181

PREAI

The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study

循环脂联素、脂联素变异与2型糖尿病心血管疾病的关系: Fremantle糖尿病研究

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2018-09-0110

PREAI

The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II

MEDICAL JOURNAL OF AUSTRALIA

IF8.5

2017-10-1619

PREAI

Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

DIABETES CARE

IF16.6

2017-08-2959

OAAI

Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study

JOURNAL OF ALZHEIMERS DISEASE

IF3.1

2017-02-0317

PREAI

Kirsten E. Peters

个人简介

教育背景

工作经历

荣誉奖项

研究方向